TY - JOUR
T1 - Structural investigation of pathogenic variants in dihydropyrimidinase using molecular dynamics simulations
AU - Kato, Koichi
AU - Nakayoshi, Tomoki
AU - Nagura, Ayuka
AU - Hishinuma, Eiji
AU - Hiratsuka, Masahiro
AU - Kurimoto, Eiji
AU - Oda, Akifumi
N1 - Funding Information:
This work was supported by Grants-in-Aid for Scientific Research ( 17K08257 ) from the Japan Society for the Promotion of Science .
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/12
Y1 - 2022/12
N2 - Dihydropyrimidinase (DHP) is an enzyme that catabolizes the degradation of pyrimidine and fluoropyrimidine drugs such as 5-fluorouracil. DHP deficiency triggers various clinical symptoms and increases the risk of fluoropyrimidine drug toxicity. Various pathogenic variants of DHP cause DHP deficiency, and their catalytic activities have been well studied. However, the three-dimensional structures of DHP variants have not been clarified. In this study, we investigated the effects of mutations on DHP structures using the molecular dynamics simulations. Simulations of the wild type and 10 variants were performed and compared. In the T68R, D81G, G278D, and L337P variants, the flexibilities of structures related to the interaction for oligomer formation increased in comparison with those of the wild type. W117R, T343A, and R412 M mutations affected the structures of stereochemistry gate loops or the substrate-binding pocket. The three-dimensional structures of W360R and G435R variants were suggested to collapse. On the other hand, only slight structural changes were observed in the R181W variant, whose experimentally observed activity was similar to that of the wild type. The computational results are expected to clarify the relationship between clinical mutations and structural effects of drug-metabolizing enzymes.
AB - Dihydropyrimidinase (DHP) is an enzyme that catabolizes the degradation of pyrimidine and fluoropyrimidine drugs such as 5-fluorouracil. DHP deficiency triggers various clinical symptoms and increases the risk of fluoropyrimidine drug toxicity. Various pathogenic variants of DHP cause DHP deficiency, and their catalytic activities have been well studied. However, the three-dimensional structures of DHP variants have not been clarified. In this study, we investigated the effects of mutations on DHP structures using the molecular dynamics simulations. Simulations of the wild type and 10 variants were performed and compared. In the T68R, D81G, G278D, and L337P variants, the flexibilities of structures related to the interaction for oligomer formation increased in comparison with those of the wild type. W117R, T343A, and R412 M mutations affected the structures of stereochemistry gate loops or the substrate-binding pocket. The three-dimensional structures of W360R and G435R variants were suggested to collapse. On the other hand, only slight structural changes were observed in the R181W variant, whose experimentally observed activity was similar to that of the wild type. The computational results are expected to clarify the relationship between clinical mutations and structural effects of drug-metabolizing enzymes.
KW - Dihydropyrimidinase
KW - Drug-metabolizing enzyme
KW - Genetic polymorphism
KW - Molecular dynamics simulation
KW - Pathogenic variant
UR - http://www.scopus.com/inward/record.url?scp=85135708088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135708088&partnerID=8YFLogxK
U2 - 10.1016/j.jmgm.2022.108288
DO - 10.1016/j.jmgm.2022.108288
M3 - Article
C2 - 35961217
AN - SCOPUS:85135708088
SN - 1093-3263
VL - 117
JO - Journal of Molecular Graphics and Modelling
JF - Journal of Molecular Graphics and Modelling
M1 - 108288
ER -